[Back to Our Trials]

EZH-302: A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

Condition: Follicular Lymphoma


Go To Trial Homepage


For more information you may call clinical trials department directly at 732-390-7750 or email us at astera.clinicaltrial@asterahealthcare.org.